Article

FDA accepts new drug application for ophthalmic NSAID

The FDA has approved Alcon Laboratories’ new drug application for nepafenac ophthalmic suspension 0.1% (Nevanac) for the treatment of pain and inflammation associated with cataract surgery. The company anticipates the ophthalmic nonsteroidal anti-inflammatory drug (NSAID) will be commercially available in several weeks.

The FDA has approved Alcon Laboratories’ new drug application for nepafenac ophthalmic suspension 0.1% (Nevanac) for the treatment of pain and inflammation associated with cataract surgery. The company anticipates the ophthalmic nonsteroidal anti-inflammatory drug (NSAID) will be commercially available in several weeks.

The suspension contains a novel prodrug that rapidly penetrates ocular tissues. The approval was based on two multicenter, placebo-controlled studies involving more than 680 patients.

In these studies, more than 80% of patients treated with the nepafenac ophthalmic suspension were pain-free the day after surgery, compared with less than 50% in the placebo group, according to Alcon. After 14 days of treatment, 95% of patients taking the suspension were pain-free, compared with 45% of patients taking the placebo, the company said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.